More than 30 million Americans have Type 2 diabetes (T2D). The World Health Organization estimates that global prevalence may be as high as 8.7% in adults over 18, rendering Type 2 diabetes as the seventh-leading cause of death worldwide.
Among the millions of patients with Type 2 diabetes, a subset of patients with chronic kidney disease (CKD) is increasing at an alarming rate. Options for safe and effective glucose control in CKD patients are extremely limited.
For the past 60 years, metformin has been the go-to treatment for controlling high blood sugar in patients with Type 2 diabetes. Here’s the problem: current formulations of metformin cannot be used safely by Type 2 patients with CKD. These patients can experience severe, sometimes even fatal side effects with current metformin dosage forms. CKD patients seeking better glucose control urgently need safe and effective treatment options.
Anji is currently developing ANJ900 (Metformin DR), whose primary site of action is the gut. This approach minimizes metformin absorption and offers a safer option for patients with advanced CKD.
Anji Pharmaceuticals is conducting Phase 3 trials to expand treatment options for T2D patients with chronic kidney disease.